Methods and materials for identifying and treating membranous nephropathy
US-2024353404-A1 · Oct 24, 2024 · US
Single domain antibodies capable of modulating bace activity
US2016237166A9 · US · A9
| Field | Value |
|---|---|
| Publication number | US-2016237166-A9 |
| Application number | US-201314023586-A |
| Country | US |
| Kind code | A9 |
| Filing date | Sep 11, 2013 |
| Priority date | Apr 3, 2008 |
| Publication date | Aug 18, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
First claim
Opening claim text (preview).
What is claimed is: 1 . An isolated single domain antibody, devoid of a light chain, wherein the single domain antibody specifically binds beta secretase (BACE1) and is able to inhibit cleavage of beta amyloid precursor protein (APP) as determined in a cellular assay. 2 . The isolated single domain antibody of claim 1 , wherein the single domain antibody is derived from camelids. 3 . A medicament comprising: the isolated single domain…
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016237166A9 cover?
- Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's d…
- Who is the assignee on this patent?
- Vib Vzw, Univ Leuven Kath, Univ Brussel Vrije
- What technology area does this patent fall under?
- Primary CPC classification C07K16/40. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Aug 18 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A9). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).